Skip to main content

Oprelvekin Pregnancy and Breastfeeding Warnings

Brand names: Neumega

Oprelvekin Pregnancy Warnings

Animal studies have revealed evidence of embryolethality at doses that produced maternal toxicity. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Comments: Female patients of childbearing potential should be advised of the possible risks to the fetus.

See references

Oprelvekin Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. Product Information. Neumega (oprelvekin). Genetics Institute. 2001.

References for breastfeeding information

  1. Product Information. Neumega (oprelvekin). Genetics Institute. 2001.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.